Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national
national blog main
national top stories
roche
4
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
glaxosmithkline
new york blog main
new york top stories
pfizer
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
amgen
biogen
bristol-myers squibb
cancer
cancer immunotherapy
clinical trials
crispr
crispr therapeutics
crispr-cas9
cystic fibrosis
What
crispr
4
×
bio
roundup
ceo
access
acquisitions
advanced
albert
alliance
big
biggest
bosley's
bosley’s
bourla
bridge
bristol
bucks
buy
calls
capacity
car
cas
cell
changing
color
company
consolidation
crime
days
departure
drug
editas
exit
falcon
focus
future
gene
growing
guiding
hours
Language
unset
unknown
Current search:
roche
×
crispr
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
